Tempest Therapeutics, Inc.
TPST
$0.00
Change (1 day)
$6.00
Year High
$0.80
Year Low
Categories
Tempest Therapeutics Inc., a clinical-stage oncology company, engages in developing small molecule therapeutics to treat cancer. The company's two clinical programs are TPST-1495, a dual antagonist of EP2 and EP4, receptors of prostaglandin E2, and is currently in a Phase 1 trial in solid tumors; and TPST-1120, a selective antagonist of peroxisome proliferator-activated receptor alpha that is in a Phase 1 trial in solid tumors. It also develops TREX-1, a key cellular enzyme that regulates the innate immune response in tumors. The company was founded in 2011 and is headquartered in South San Francisco, California. Tempest Therapeutics Inc. was formerly a subsidiary of Inception Sciences, Inc.
Tempest Therapeutics, Inc. (TPST) - Company Outlook
Company Outlook
| Year | Receivables | Debt | Liabilities | Assets | Current Assets |
|---|---|---|---|---|---|
| 2023 | -18,569,000 | 24.84 M | 51.6 M | 40.36 M | |
| 2022 | -9,116,000 | 27.98 M | 46.09 M | 32.95 M | |
| 2021 | -33,292,000 | 37.12 M | 73.24 M | 68.96 M | |
| 2020 | 260 K | -16,381,000 | 91.66 M | 22.86 M | 19.83 M |
| 2019 | 1.28 M | -58,990,000 | 15.1 M | 74.97 M | 71.13 M |